11:47 AM EST - Medwell Capital Corp. : jointly announced with Spectral Diagnostics Inc., a Phase III company developing the first theranostic treatment for severe sepsis and septic shock a non-brokered agreement whereby Medwell and a consortium of buyers purchased in private transactions 12,449,501 common shares and 962,500 common share purchase warrants of Spectral from GrowthWorks Canadian Fund Ltd., representing 15.6% of the issued and outstanding shares. Medwell Capital Corp.
shares V.MWC are trading down $0.01 at $0.23.
